About this trial
This study aimed to analyze the distribution characteristics of Helicobacter pylori(H. pylori) in varying stages of atrophic gastritis and early gastric cancer using immunohistochemical staining, with the goal of providing guidance for the early screening of gastric cancer.
A retrospective analysis was conducted on gastric biopsy cases that underwent H. pylori immunohistochemical staining at our center from March 1, 2023, to August 15, 2025. Cases were classified into non-atrophic and atrophic groups based on the presence or absence of gastric atrophy. All cases were further divided into non-open and open atrophy groups and additionally into early gastric cancer and non-cancer groups. The distribution of H. pylori across subgroups was compared, and multivariate analyses were performed to identify risk factors associated with the development of early gastric cancer.
Eligibility criteria
Qualifiers
age 18-80 years
received H. pylori immunohistochemical testing at our center and tested positive.
Disqualifiers
biopsies not collected from both the greater and lesser curvatures of the gastric antrum and body
history of stomach surgery
suspected autoimmune gastritis under endoscopy
liver cirrhosis
Trial design
Treatments tested in this trial
- immunohistochemical testing